Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Castle earns 4 Top Workplaces Awards—Houston Top Workplace plus 3 Culture Excellence Awards—bringing their 2025 total Top Workplaces Awards to 13
November 14, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
November 11, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET
November 03, 2025 16:07 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Third Quarter 2025 Results

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the third quarter and nine months ended Sept. 30, 2025.
November 03, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

today announced the launch of AdvanceAD-Tx™, a GEP test designed to guide systemic treatment decision making in patients ages 12 and older.
October 28, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences to Participate in November Investor Conferences
October 26, 2025 15:05 ET | Source: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025.
October 24, 2025 04:05 ET | Source: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
October 13, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Castle Biosciences will release Q3 2025 financial results and host conference call on Monday, Nov. 3, 2025
October 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Castle Biosciences' Founder, President & CEO Derek Maetzold awarded CEO of the Year by The CEO Magazine